ALTH Allos Therapeutics, Inc. (MM)

Allos Therapeutics to Present at Credit Suisse First Boston's Healthcare Conference WESTMINSTER, Colo., Nov. 17 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced that the Company will participate in Credit Suisse First Boston's 2004 Healthcare Conference, to be held on November 17-19 in Phoenix, AZ. Michael E. Hart, President and Chief Executive Officer of Allos will give a 30-minute corporate overview on Friday, November 19 at 10:30 AM ET. The presentation will be webcast live and may be accessed by visiting the Allos website at http://www.allos.com/. A replay of the webcast will also be available on the company's website until Friday, December 3, 2004. About Allos Therapeutics, Inc. Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company's lead clinical candidate, EFAPROXYN(TM), is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX (pralatrexate), a novel small molecule cytoxic injectable antifolate (DHFR inhibitor) that is currently being investigated in patients with non-small cell lung cancer and non-Hodgkin's lymphoma. For more information, please visit the company's web site at: http://www.allos.com/. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer Neiman, Manager, Corporate Communications of Allos Therapeutics, +1-720-540-5227, Web site: http://www.allos.com/

Copyright